Search

ABSTRACTThe Africa Centres for Disease Control and Prevention Biosafety and Biosecurity Initiative being implemented across the 55 African Union Member States is presented. Based on consultations with Member States between 2019 and 2021, national-level capacity gaps were identified which informed the biosafety and biosecurity 5-year (2021–2025) strategic plan. The process of identifying national gaps, development, implementation and monitoring of the 5-year strategic plan is described. Notable achievements include development of a regional biosafety and biosecurity legislative framework now approved by African Union structures and process of domestication that has started in some countries; establishment and operationalisation of multi-sectoral regional biosafety and biosecurity technical working groups tasked with coordinating and monitoring implementation of the initiative, development and implementation of an accessible and regionally endorsed Regional Training and Certification Program for Biosafety and Biosecurity Professionals; establishment of a Regional Centre of Excellence for biosafety and biosecurity from where two cohorts of students in the two areas of biorisk management (16 students from 8 countries) and biological waste management (19 students from 10 countries) have been trained and development of a Regulatory and Certification Framework for Institutions Handling High-Risk Pathogens with three components of minimum standards of biosafety and biosecurity for high-containment facilities, a standard evaluation checklist for checking compliance and a certification framework for authorising performance of tasks related to dangerous pathogens. A guidance document with step-by-step process on how to translate regional successes to national implementation was developed and published. Based on notable regional successes of the initiative, Africa CDC co-chaired the Global Health Security Agenda Action Package 3 on Prevention and the Africa Signature Initiative Biosafety and Biosecurity Working Group. Challenges of delayed implementation due to the COVID-19 pandemic, limited resources to implement all planned activities and limited staff dedicated to biosafety and biosecuruty at Africa CDC.

Seth Inzaule and co-authors discuss implications of the COVID-19 pandemic for health in African countries.

Abstract Assessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV/Sinopharm, Covishield vaccine, and Pfizer/BioNTech, and one dose for Johnson & Johnson's Janssen COVID-19 vaccine). The study spanned 16 provinces in the Casablanca-Settat region from February to June 2022, during which comprehensive demographic and comorbidity data were collected. We screened samples for the presence of IgG antibodies using the SARS-CoV-2 IgG II Quant assay, which quantifies antibodies against the receptor-binding domain (RBD) of the spike (S) protein, measured on the Abbott Architect i2000SR. The overall crude seroprevalence was 96% (95% CI: 95.6–96.3%), and after adjustment for assay performance, it was estimated as 96.2% (95% CI: 95.7–96.6). The adjusted overall seroprevalences according to vaccine brands showed no significant difference (96% for BBIBP-CorV/Sinopharm, 97% for ChAdOx1 nCoV-19/Oxford/AstraZeneca, 98.5% for BNT162b2/Pfizer-BioNTech, and 98% for Janssen) (p = 0.099). Participants of older age, female sex, those with a history of previous COVID-19 infection, and those with certain chronic diseases were more likely to be seropositive among ChAdOx1 nCoV-19/Oxford/AstraZeneca and BBIBP-CorV/Sinopharm vaccinee groups. Median RBD antibody concentrations were 2355 AU/mL, 3714 AU/mL, 5838 AU/mL, and 2495 AU/mL, respectively, after two doses of BBIBP-CorV/Sinopharm, ChAdOx1 nCoV-19/Oxford/AstraZeneca, BNT162b2/Pfizer-BioNTech, and after one dose of Janssen (p 0.05). In conclusion, our serosurvey findings indicate that all four investigated vaccines provide a robust humoral immune response in the majority of participants (more than 96% of participants had antibodies against SARS-CoV-2). The BNT162b2 vaccine was found to be effective in eliciting a strong humoral response compared to the other three vaccines. However, challenges still remain in examining the dynamics and durability of immunoprotection in the Moroccan context.

Objectives: We estimated the prevalence and determinants of secondhand smoke (SHS) exposure among nonsmoking adolescents in 9 West African countries., Methods: We conducted a pooled analysis with nationally representative 2006 to 2009 Global Youth Tobacco Survey data. We used descriptive statistics to determine the prevalence of SHS exposure and inferential statistics using a multivariable logistic regression model to determine factors associated with SHS exposure. We investigated average marginal effect results that show the probability of SHS exposure, adjusting for all other attributes., Results: SHS exposure inside the home ranged from 13.0% to 45.0%; SHS exposure outside the home ranged from 24.7% to 80.1%. Parental or peer smoking behaviors were significantly associated with higher probability of SHS exposure in all 9 countries. Knowledge of smoking harm, support for smoking bans, exposure to antismoking media messages, and receptivity of school tobacco education were significantly associated with higher SHS exposure in most countries., Conclusions: West African policymakers should adopt policies consistent with Article 8 of the World Health Organization Framework Convention on Tobacco Control and its guidelines and public health education to promote smoke-free households.